Special report on the use of funds raised last time by Aidi Pharmaceutical

Securities code: 688488 Securities abbreviation: Aidi Pharmaceutical Announcement number: 2026-041

Jiangsu Aidi Pharmaceutical Group Co., Ltd.

Special report on the use of funds raised last time

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

In accordance with the provisions of the "Guidelines for the Application of Regulatory Rules - Issuance No. 7" issued by the China Securities Regulatory Commission, Jiangsu Aidi Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or the "Company") has prepared a special report on the use of the previous raised funds as of December 31, 2025. The details are as follows:

1. Basic information on the previous fundraising

(1) The amount of funds raised last time and the time when the funds will be received

1. Fund raising from initial public offering of shares in July 2020

Approved by the China Securities Regulatory Commission’s “Reply on Approving the Registration of the Initial Public Offering of Jiangsu Aidi Pharmaceutical Co., Ltd.” (CSRC License [2020] No. 1185), the company publicly issued 60,000,000 RMB ordinary shares to the public, with a face value of RMB 1.00 per share, an issue price of RMB 13.99 per share, and a total amount of funds raised of RMB 839,400,000.00. After deducting underwriting and sponsorship fees, the total tax-included amount was RMB 61,758,000.00, and the actual raised funds were RMB 777,642,000.00. The cumulative issuance expenses of this stock issuance include tax of RMB 79,833,781.03, including the deductible value-added tax input tax of RMB 4,506,826.42. After deducting the issuance expenses excluding tax, the net amount of funds raised is RMB 764,073,045.39.

The above-mentioned raised funds were remitted to the company's special RMB account 9550880058239300203 opened at China Guangfa Bank Co., Ltd. on July 13, 2020. Rongcheng Accounting Firm (Special General Partnership) verified the arrival of the funds raised in this issuance and issued a "Capital Verification Report" No. Rongcheng Yanzi [2020] 210Z0012. The Company adopts a special account storage system for raised funds.

2. Raised funds management system and regulatory agreement

In accordance with relevant laws and regulations and the provisions of the "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations" and following the principles of standardization, safety, efficiency and transparency, the company has formulated the "Management Measures for Raised Funds", which clearly stipulates the storage, approval, use, management and supervision of raised funds to institutionally ensure the standardized use of raised funds.

On June 30, 2020, the Company signed the "Three-Party Supervision Agreement for the Special Account Deposit of Raised Funds" with China Construction Bank Co., Ltd. Yangzhou Branch and Huatai United Securities, and opened a special account for raised funds (account number: 32050174513609066666) at China Construction Bank Co., Ltd. Yangzhou Branch (Chengdong Branch).

June 30, 2020 On the same day, the Company signed the "Five-Party Supervision Agreement for Special Account Deposit of Raised Funds" with its subsidiaries Nanjing Ansailai Pharmaceutical Technology Co., Ltd., Guangfa Bank Co., Ltd. Yangzhou Branch, China Construction Bank Co., Ltd. Nanjing Gulou Branch and Huatai United Securities. Open a special account for raised funds (account number: 9550880058239300203), and open a special account for raised funds at China Construction Bank Co., Ltd. Nanjing Gulou Branch (Jianning Road Branch) (account number: 32050159524609999996).

On June 30, 2020, the company signed the "Four-Party Supervision Agreement for Special Account Deposit of Raised Funds" with its subsidiaries Yangzhou Aidi Pharmaceutical Technology Co., Ltd., Bank of Jiangsu Co., Ltd. Yangzhou Branch and Huatai United Securities, and opened a special account for raised funds (account number: 90160188000125327) at the Yangzhou Branch of Bank of Jiangsu Co., Ltd. (Tangcheng Branch).

On January 19, 2022, the company held the 21st meeting of the first board of directors and the 17th meeting of the first board of supervisors, and reviewed and approved the "Proposal on Changing Part of the Special Account for Raised Funds and Adding a New Special Account for Raised Funds".

On January 26, 2022, the company signed the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" with China Construction Bank Co., Ltd. Jiangsu Branch and Huatai United Securities, and opened a special account for raised funds (account number: 32050174513600001886) at China Construction Bank Co., Ltd. Yangzhou Branch (Chengdong Branch).

On February 21, 2022, the company signed the "Four-Party Supervision Agreement for Special Account Deposit of Raised Funds" with its subsidiary Nanjing Aidi Pharmaceutical Technology Co., Ltd., Nanjing Gulou Branch of China Construction Bank Co., Ltd. and Huatai United Securities, and opened a special account for raised funds at the Nanjing Gulou Branch of China Construction Bank Co., Ltd. (account number: 32050159524609111111).

On March 3, 2022, the company has canceled the special account at the Yangzhou Branch of Guangfa Bank Co., Ltd. (account number: 9550880058239300203), and transferred all the principal and interest balance of the original raised funds special account to the new special account for raised funds opened at the Yangzhou Branch of China Construction Bank Co., Ltd. (account number: 32050174513600001886).

On October 27, 2023, the company signed the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" with its subsidiaries Chengdu Aidi Medical Technology Co., Ltd., High-tech Branch of Bank of Chengdu Co., Ltd. and Huatai United Securities, and opened a special account for raised funds at the High-tech Branch of Bank of Chengdu Co., Ltd. (account number: 1001300001151309).

On June 27, 2025, the Company signed the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" with Bank of Jiangsu Co., Ltd. Yangzhou Branch and Huatai United Securities, and opened a special account for temporary supplementary liquidity of raised funds (account number: 90030188000138108) at Bank of Jiangsu Co., Ltd. Yangzhou Branch (Shugang Branch).

On June 27, 2025, the Company signed the "Tripartite Supervision Agreement for Special Account Deposit of Raised Funds" with China Merchants Bank Co., Ltd. Yangzhou Branch and Huatai United Securities, and opened a special account for temporary supplementary liquidity of raised funds (account number: 514902448810003) at the Yangzhou Branch of China Merchants Bank Co., Ltd. (Hanjiang Branch).

There are no major differences between the main terms of the above-mentioned supervision agreement and the Shanghai Stock Exchange's "Tripartite Supervision Agreement for Separate Account Storage of Raised Funds (Template)", and there are no problems with the performance of the supervision agreement.

(2) Deposit status of previously raised funds in special accounts

As of December 31, 2025, the storage status of raised funds is as follows:

Unit: RMB 10,000

Company name Name of bank where raised funds are deposited Bank account number Initial deposit amount Closing balance Remarks Jiangsu Aidi Pharmaceutical Group Guangfa Bank Co., Ltd. Yangzhou Branch 955088005823 Sold

77,764.20 -

Tuan Group Co., Ltd. Bank No. 9300203 Jiangsu Aidi Pharmaceutical Group China Construction Bank Co., Ltd. Yang 320501745136

• 4,253.88

Tuan Co., Ltd. Zhou Branch (Chengdong Branch) 00001886

Jiangsu Aidi Pharmaceutical Group China Construction Bank Co., Ltd. Yang 320501745136

• 119.76

Tuan Co., Ltd. Zhou Branch (Chengdong Branch) 09066666

Yangzhou Aidi Medical Branch Bank of Jiangsu Co., Ltd. Yangzhou Branch 901601880001

• 662.83

Technology Co., Ltd. Branch (Tangcheng Branch) 25327

Nanjing Arcelite Pharmaceuticals China Construction Bank Co., Ltd. South 320501595246

• 895.51

Technology Co., Ltd. Jinggulou Branch (Jianning Road Branch) 09999996

Note: Nanjing Aidi Medical Co., Ltd. China Construction Bank Co., Ltd. South 320501595246

• 10.77

Technology Co., Ltd. Jinggulou Branch (Jianning Road Branch) 09111111

Chengdu Aidi Medical Technology High-tech Branch of Bank of Chengdu Co., Ltd. 100130000115

• 1,053.39

Technology Co., Ltd. Branch (Free Trade Zone Branch) 1309

Jiangsu Aidi Pharmaceutical Group Bank of Jiangsu Co., Ltd. Yangzhou Branch 900301880001

Tuan Co., Ltd. Branch (Shugang Branch) 38108

514902448810

Jiangsu Aidi Pharmaceutical Group China Merchants Bank Co., Ltd. Yangzhou Branch - -

Company name Name of bank where raised funds are deposited Bank account number Initial deposit amount Closing balance Note Tuan Co., Ltd. Bank (Hanjiang Branch)

Total 77,764.20 6,996.13

Note: The account of Nanjing Jianning Road Branch of China Construction Bank Co., Ltd. contains 2,300.00 yuan of non-raised funds. To open a raised fund account, a pre-deposit of 2,300.00 yuan is required.

2. Actual use of funds raised last time

(1) Usage of raised funds

Unit: RMB

Item Amount

Total amount of raised funds actually received in July 2020 777,642,000.00 Less: Replacement of raised funds for the amount of tax-included issuance fees paid in advance 5,233,415.00 Less: Amount of tax-included issuance fees paid 12,651,300.00 Less: Use of raised funds to replace the self-raised funds that have been invested in investment projects with raised funds in advance

Amount of 130,000,770.02

Less: Amount of using excess raised funds to permanently replenish working capital 13,657,285.00 Less: Amount of project balance funds to permanently replenish working capital 33,329,317.31 Less: Amount directly invested in raised funds projects 476,540,250.14 Less: Amount of using idle raised funds to temporarily replenish working capital - Less: Raised funds cash management investment 80,000,000.00 plus: Net interest income and investment income after deducting handling fees 43,729,350.65 Balance of current deposits of raised funds on December 31, 2025 69,959,013.18

(2) Changes in actual investment projects with previously raised funds

As of December 31, 2025, the specific use of funds in the Company's changes to investment projects with raised funds is detailed in Appendix 2: Table of Changes in Investment Projects with Raised Funds.

(3) Changes in the implementation location and implementation method of the previous fund-raising project

As of December 31, 2025, there were no changes in the implementation location and implementation method of the company's previous fund-raising projects.

(4) Explanation of the differences between the actual total investment amount of the previous fund-raising project and the commitment and the reasons

For the difference between the actual total investment and the commitment of the company's previous raised funds project, please refer to Appendix 1: Comparison table of the use of previously raised funds.

Reasons for differences in API production, R&D and supporting facilities projects: During the construction process of API production, R&D and supporting facilities projects, the company started from the actual situation of the project, and on the premise of ensuring project quality, adhered to the principles of prudence, reasonableness, economy and effectiveness, strengthened the control, supervision and management of costs in all aspects of project construction, and reasonably reduced the total project expenditure; in addition, the raised investment project received a number of government subsidies totaling approximately RMB 4,989 in 2021 and 2022. Ten thousand yuan, it is more conducive to generating savings from the funds raised by the investment project when the government subsidy funds are used first. At the same time, in order to seek more investment returns for the company's shareholders and improve the efficiency of the use of raised funds, the company carried out cash management of idle raised funds and obtained a certain amount of interest and financial management income on the premise of ensuring the construction progress of the raised investment projects.

In addition to the above-mentioned projects, the reason for differences in other projects is that they have not yet been completed.

(5) Usage of temporarily idle raised funds

The company held the 11th meeting of the first board of directors and the 7th meeting of the first board of supervisors on August 19, 2020, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" respectively, agreeing that the company can use temporarily idle raised funds up to a maximum of RMB 600 million for cash management, with a use period of no more than 12 months. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis; the independent directors have issued clear independent opinions of agreement, and the sponsor Huatai United Securities Co., Ltd. (hereinafter referred to as the "sponsor") has issued clear verification opinions on this matter. The above matters are within the scope of the board of directors' approval authority and do not need to be submitted to the shareholders' meeting for review.

The company held the 18th meeting of the first board of directors and the 14th meeting of the first board of supervisors on August 26, 2021, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" respectively, agreeing that the company will use temporarily idle raised funds up to a maximum of RMB 450 million for cash management, with a use period of no more than 12 months. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis; the independent directors have issued independent opinions clearly agreeing, and the sponsor has issued verification opinions. The above matters are within the scope of the board of directors' approval authority and do not need to be submitted to the shareholders' meeting for review.

The company held the eighth meeting of the second board of directors and the seventh meeting of the second board of supervisors on September 13, 2022, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" respectively, agreeing that the company can use temporarily idle raised funds up to a maximum of RMB 380 million for cash management, with a use period of no more than 12 months. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis; the independent directors have issued independent opinions clearly agreeing, and the sponsor has issued verification opinions. The above matters are within the scope of the board of directors' approval authority and do not need to be submitted to the shareholders' meeting for review.

The company held the 12th meeting of the second board of directors and the 11th meeting of the second board of supervisors on April 14, 2023, and reviewed and approved the "Proposal on the Use and Renewal of Temporarily Idle Raised Funds for Cash Management" respectively, agreeing that the company can use temporarily idle raised funds up to a maximum of RMB 380 million for cash management, with a use period of no more than 12 months. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis; the independent directors have issued independent opinions clearly agreeing, and the sponsor has issued verification opinions. The above matters are within the scope of the board of directors' approval authority and do not need to be submitted to the shareholders' meeting for review.

The company held the 20th meeting of the second board of directors and the 19th meeting of the second board of supervisors on March 25, 2024, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" respectively, clearly agreeing that the company will use temporarily idle raised funds up to a maximum of RMB 250 million for cash management, and the period of use will be from the expiration date of the authorization for cash management of the previous idle raised funds 12 It will be valid within one month, that is, from April 14, 2024 to April 13, 2025; if the validity period of a single transaction exceeds the validity period of the resolution, the validity period of the resolution will be automatically extended until the termination of the single transaction. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis; the sponsor has issued a verification opinion. The above matters are within the scope of the board of directors' approval authority and do not need to be submitted to the shareholders' meeting for review.

On April 15, 2024, the company held the 21st meeting of the second board of directors and the 20th meeting of the second board of supervisors, and reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", and agreed that in order to improve the efficiency of the use of raised funds and reduce the company's financial costs, the company and its subsidiaries plan to use part of the idle raised funds not to exceed 1.50 without affecting the construction progress of the investment projects with raised funds. The RMB 100 million will be used to temporarily replenish working capital, which will only be used for production and operations related to the main business, and the period of use shall not exceed 12 months from the date of approval by the board of directors. The sponsor issued a clear verification opinion on this matter. This matter is within the scope of the board of directors' approval authority and does not need to be submitted to the shareholders' meeting for consideration.

The company held the second meeting of the third board of directors and the second meeting of the third board of supervisors on February 27, 2025, and reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", and agreed that in order to improve the efficiency of the use of raised funds and reduce the company's financial costs, the company and its subsidiaries plan to use part of the idle raised funds not to exceed RMB 1.5 while ensuring that the construction progress of the investment project with raised funds (hereinafter referred to as the "raised investment project") will not be affected. The RMB 100 million will be used to temporarily replenish working capital, which will only be used for business development, daily operations and other production and operations related to the main business. The use period shall not exceed 12 months from the date of approval by the board of directors. The sponsor issued a clear verification opinion on this matter. The company opened a special account for temporary replenishment of raised funds on June 27, 2025, and has transferred the current temporary replenishment funds back to the special account for raised funds, and will implement replenishment through the special account for raised funds in the future.

The company held the second meeting of the third board of directors and the second meeting of the third board of supervisors on February 27, 2025, and reviewed and approved the "Proposal on the Use of Temporarily Idle Raised Funds for Cash Management" respectively, agreeing that the company (including subsidiaries, the same below) can use temporarily idle raised funds up to a maximum of RMB 195 million for cash management. The use period is valid for 12 months from the expiration date of the authorization for cash management of the previous idle raised funds, which is April 14, 2025. Valid until April 13, 2026. Within the aforementioned quota and period, the company can use this part of the idle raised funds on a rolling basis. The sponsor issued a clear verification opinion on this matter. This matter is within the scope of the board of directors' approval authority and does not need to be submitted to the shareholders' meeting for consideration.

As of December 31, 2025, the company used idle raised funds for cash management with a balance of 80 million yuan, and accumulated financial management income of 37.2539 million yuan and related interest income of 713,700 yuan.

(6) Use of excess raised funds to permanently supplement working capital or return bank loans

The company held the 11th meeting of the first board of directors and the 7th meeting of the first board of supervisors on August 19, 2020. They reviewed and approved the "Proposal on the Use of Raised Funds for Permanent Replenishment of Liquidity" respectively, and agreed to use part of the over-raised funds of 5.3 million yuan for permanent replenishment of liquidity. The company's independent directors issued independent opinions clearly agreeing, and the sponsor Huatai United Securities issued a verification opinion.

The company held the 18th meeting of the first board of directors and the 14th meeting of the first board of supervisors on August 26, 2021. They reviewed and approved the "Proposal on the Use of Raised Funds for Permanent Replenishment of Liquidity" respectively, and agreed to use 5.3 million yuan of super-raised funds to permanently replenish liquidity. The company's independent directors issued independent opinions clearly agreeing, and the sponsor Huatai United Securities Co., Ltd. issued a verification opinion.

The company held the eighth meeting of the second board of directors and the seventh meeting of the second board of supervisors on September 13, 2022. They reviewed and approved the "Proposal on Using Part of the Over-raised Funds for Permanent Replenishment of Working Capital" respectively, and agreed to use part of the over-raised funds of 5.3 million yuan to permanently replenish working capital. The company's independent directors issued independent opinions clearly agreeing, and the sponsor Huatai United Securities issued a verification opinion.

As of December 31, 2025, the company has used over-raised funds to permanently replenish working capital of RMB 13.6573 million, and the over-raised funds have been used up.

(7) External transfer or replacement of investment projects with previously raised funds

The company held the fifth meeting of the third board of directors and the fifth meeting of the third board of supervisors on August 14, 2025, and reviewed and approved the "Proposal on Using Own Funds, Bank Acceptance Bills and Other Methods to Pay the Funds Required for Raised Investment Projects and Replacement with Raised Funds in Equal Parts." According to the "Supervision Rules for Funds Raised by Listed Companies" and other regulations, if it is really difficult to directly pay the raised funds, without affecting the normal implementation of the raised investment project, the company and its subsidiaries that implement the raised investment project can use their own funds, bank acceptance bills, etc., to pay for the funds required for the raised investment project and replace them with raised funds in equal amounts, based on the specific circumstances of the implementation of the raised investment project. This part of the equal amount of replacement funds will be regarded as the funds used for the raised investment project. The sponsor issued a verification opinion on the company's use of its own funds, bank acceptance bills and other methods to pay for the funds required for the investment project and to replace it with the raised funds in equal amounts.

The company held the 11th meeting of the first board of directors and the 7th meeting of the first board of supervisors on August 19, 2020, and reviewed and approved the "Proposal on the Use of Raised Funds to Replace Pre-invested Self-raised Funds" respectively. The independent directors and the Supervisory Board clearly agreed that the company would use raised funds to replace 130,008,000 yuan of self-raised funds and 523.34 million yuan of issuance fees and value-added tax that had been invested in investment projects with raised funds in advance. 10,000 yuan, with a total replacement of 135.2342 million yuan.

The above-mentioned pre-investment of raised funds into investment projects with self-raised funds has been verified by Rongcheng Accounting Firm (Special General Partnership) and issued the "Authentication Report on Jiangsu Aidi Pharmaceutical Co., Ltd.'s pre-investment of raised funds with self-raised funds in investment projects" (Rongcheng Zhuanzi [2020] 210Z0076). The company's independent directors have expressed clear approval opinions on the above matters, and Huatai United Securities has issued clear approval verification opinions on the above matters.

The details of the replacement of pre-invested self-raised funds with raised funds are as follows:

Unit: 10,000 yuan

Commitment to invest raised funds Self-raised funds pre-investment serial number Project name Project content

Fund Amount Amount

ACC007 Phase III/IV clinical project 5,610 2,660.28 ACC008 Phase III/IV clinical project 9,020 20.32 Innovative drug research and development ACC006BCC Phase II clinical project 3,340 - and R&D technology

1 ACC006 lung squamous cell carcinoma combined with chemotherapy phase II clinical project 7,010 477.83 Center Building

Purchase project ACC006PD-1 combination phase II clinical project 5,260 - ACC010I/II phase clinical project 5,340 92.90 R&D technology center building purchase project 3,700 - 2 API production R&D and supporting facilities project 20,330 202.13 3 Repayment of bank loans and supplement of working capital 15,000 9,546.62 Total 74,610 13,000.08 Except for the above-mentioned substitutions, there are no other substitutions.

(8) Explanation of the unused funds raised in the previous round

The company's net raised funds from the initial public offering of stocks in July 2020 was RMB 764.073 million. As of December 31, 2025, the total amount of raised funds invested was RMB 671.4123 million. The balance of idle raised funds for cash management was RMB 80.00 million. The balance of current deposits of raised funds was RMB 80.00 million. 69.959 million yuan (including the accumulated bank deposit interest received minus bank handling fees and the net investment income of 43.7294 million yuan obtained by using idle raised funds to purchase financial products). The main reason why the funds raised in the previous round were not fully used is detailed in the second item of this article: "(4) The difference between the actual total investment in the project raised in the previous round and the commitment and the explanation of the reasons."

3. Economic benefits generated by investment projects with previously raised funds

As of December 31, 2025, the company's initial public offering of shares to raise funds for the investment project integrase inhibitor drug research and development and its clinical research projects, and HIV high-end generic drug research and development projects have not yet been completed.

The ACC008 Phase III/IV clinical project and the Ibond® (Anovirine Tablets) Phase III clinical and post-marketing research project will reach the scheduled ready-to-use status in December 2025.

The API production R&D and supporting facilities project was completed in March 2023, and a production license has been obtained. It will pass the GMP compliance inspection in June 2024 and start production.

For details on the benefits realized by the company’s investment projects with previously raised funds, please see Appendix 3: Comparison table of benefits realized by projects invested with previously raised funds.

4. Comparison of information disclosure on the actual use of funds raised in the previous round

There is no difference between the actual use of funds raised by the company and the relevant content disclosed in the company's external information disclosure documents.

Attachment 1: Comparison table of the use of funds raised last time

Appendix 2: Changes in investment projects with raised funds

Attachment 3: Comparison table of benefits achieved by investment projects with previously raised funds

Board of Directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd.

March 31, 2026

Schedule 1:

Comparison table of usage of funds raised last time

As of December 31, 2025

Prepared by: Jiangsu Aidi Pharmaceutical Group Co., Ltd. Unit: RMB 10,000

Total raised funds 77,764.20 Cumulative amount of raised funds invested: 67,141.23

Total funds invested and raised in each year: 67,141.23

Total amount of raised funds changed in use 26,158.75

2020: 18,684.11

2021: 14,472.32

2022: 7,107.84

2023: 11,633.41

Proportion of total funds raised with changed purposes 33.64% 2024: 9,989.85

2025: 5,253.70

Accumulated by the end of the period. The project may have changed. Raised funds. Investment by the end of the period.

After adjustment, as of the end of the period, the project has achieved the expected amount of investment. Is it feasible?

Project, including financial commitments, funds invested, progress

Committed investment projects Total investment Committed investment Cumulative investment Determined usable status with committed investment Whether the realized benefits have been partially changed to the expected Total investment (%) (4) = (2)

Amount Amount(1) Amount(2) Difference in amount Status date Benefit Major changes (if any) Amount/(1)

(3)=(2)-(1)

ACC008III/IV

Phase 1 clinical project No 9,020.00 9,020.00 9,020.00 8,302.62 8,302.62 -717.38 92.05 December 2025 Not applicable Not applicable No

Aibond® (Aino

Weilin Tablets) Phase III Pro December 2026

• 10,050.00 10,050.00 7,807.71 7,807.71 -2,242.29 77.69

Clinical and post-marketing research Yes (Note 3) Not applicable Not applicable No research project

integrase inhibitor

Drug research and development and its Yes - 15,446.99 15,446.99 9,156.11 9,156.11 -6,290.88 59.27 December 2027 Not applicable Not applicable No clinical research project

High-end HIV generics

Drug R&D project Yes - 3,700.00 3,700.00 1,830.21 1,830.21 -1,869.79 49.47 December 2026 Not applicable Not applicable No API production and research

Development and supporting facilities No 20,330.00 20,330.00 20,330.00 17,494.44 17,494.44 -2,835.56 86.05 (Note 1) December 2022 177.91 Not applicable No project

Ulinastatin Xinshi

Yes 0.00 1,063.01 1,063.01 1,063.01 1,063.01 - - - Not applicable Not applicable It is a disease-specific research project

ACC007Ⅲ/Ⅳ

Phase 1 clinical project Yes 5,610.00 - - - - - - - Not applicable Not applicable No (Note 2)

ACC006BCC

Phase II clinical project Yes 3,340.00 - - - - - - - Not applicable Not applicable This is the purpose

ACC006 Lung scales

Cancer chemotherapy combination II Yes 7,010.00 - - - - - - - Not applicable Not applicable This is a clinical project

ACC006PD-1

Combined Phase IⅡ Clinical Yes 5,260.00 - - - - - - - Not applicable Not applicable It is a bed project

ACC010I/II period

Clinical projects Yes 5,340.00 - - - - - - - Not applicable Not applicable Yes

R&D Technology Center

Building purchase project Yes 3,700.00 - - - - - - - Not applicable Not applicable It is to repay the bank loan

and supplementary working capital No 15,000.00 15,000.00 15,000.00 15,000.00 15,000.00 - 100.00 - Not applicable Not applicable No funds

Commitment to investment projects

Subtotal - 74,610.00 74,610.00 74,610.00 60,654.10 60,654.10 -13,955.90 -

Pay issuance fees

and supplement of over-raised funds - 3,154.20 3,154.20 3,154.20 3,154.20 3,154.20 - 100.00 - Not applicable Not applicable - To replenish working capital

Project balance funds

Permanent replenishment flow - - - - 3,332.93 3,332.93 3,332.93 - - Not applicable Not applicable - Funds

Total 77,764.20 77,764.20 77,764.20 67,141.23 67,141.23 -10,622.97 - - -

Reasons for failure to meet planned progress (divided into specific projects) None as of December 31, 2025.

There is a risk of significant changes in the feasibility of research projects for new indications of ulinastatin. The company held the 21st meeting of the second board of directors and the 20th meeting of the second board of supervisors on April 15, 2024, and agreed that the company would adjust the "date of reaching the scheduled usable status" of the raised investment project to June 30, 2025. Although the project has been postponed, as of June 2025, CDE still recommends further evaluating and demonstrating product quality control strategies on the basis of the research and demonstration already carried out, and the objective environment of the Center for Drug Evaluation of the State Food and Drug Administration’s higher requirements for drug clinical trials has not changed.

ization, therefore during the subsequent advancement of this project, there is still the risk of significant changes in the feasibility of the project.

Description of major changes in project feasibility

In order to improve the efficiency of the use of raised funds, on June 27, 2025, after deliberation at the fourth meeting of the company's third board of directors and the fourth meeting of the third board of supervisors, the "Proposal on Changes in Investment Projects and Amount Adjustments of Partially Raised Funds" was adopted, and the original projects were The balance of RMB 84.3699 million of the raised funds of the "Ulinastatin New Indications Research Project" was completely changed to the existing fundraising project "Integrate Inhibitor Drug Research and Development and Clinical Research Project". This matter has been reviewed and approved by the second extraordinary shareholders' meeting on July 14, 2025 and became effective.

Note 1: The "API Production R&D and Supporting Facilities Project" was completed in March 2023. At the end of this period, the uninvested amount of this project was 28.3556 million yuan, including 4.5078 million yuan of unpaid engineering funds and other funds. The remaining balance of raised funds for permanent replenishment is 23.8478 million yuan (the difference of 9.4815 million yuan between 23.8478 million yuan and 33.3293 million yuan is the net cash management income and interest in the transferred-out balance funds).

Note 2: The "ACC007 Phase III/IV clinical project" was reviewed at the 18th meeting of the company's first board of directors and the 14th meeting of the first board of supervisors on August 26, 2021. It was reviewed at the company's third extraordinary shareholders' meeting in 2021 on September 14, 2021, and the project was changed to "Ibond® (Anovirin Tablets) III "Phase clinical and post-marketing research project" and the investment amount to be used to raise funds is increased from the initial RMB 56.10 million to RMB 100.5 million; this change is the name change of the same project and the investment amount is increased. Therefore, the amount of raised funds of RMB 41.0125 million that has been spent under the "ACC007 III/IV phase clinical project" before the project change is listed in the post-change project "Aibunde® (Inovirin Tablets) III" in the above table The accumulated amount of funds raised under "Phase-1 clinical and post-marketing research projects" is included in the "cumulative investment amount as of the end of the period".

Note 3: The Phase III clinical and post-marketing research project of Ibond® (Elanovirine Tablets) will actually reach the scheduled usable status in December 2025.

Schedule 2:

Changes to the investment project status of raised funds

As of December 31, 2025

Prepared by: Jiangsu Aidi Pharmaceutical Group Co., Ltd. Unit: RMB 10,000

After the change, the project is planned to be invested as of the end of the period.

Actual cumulative investment Investment progress (%)

The project can reach the scheduled

Whether the realized effect has achieved the expected effect. The changed project can correspond to the original project after the change. The actual investment amount. Whether the total amount of raised funds has been reintroduced into the project. Total investment amount (1) Amount (2)

(3)=(2)/(1)

Use status date benefit benefit

Big Change AiBond® (Aino ACC007III/IV Phase Pro

Weilin tablets) Phase III bed project

10,050.00 10,050.00 7,807.71 7,807.71 77.69 December 2026 Not applicable Not applicable No Clinical and post-marketing

ACC010I/II clinical trial

Research project (Note 1)

Project

Ulinastatin Xinzhi ACC006BCCII Phase II

Disease research project Bed project 9,500.00 - 1,063.01 1,063.01 - June 2025 Not applicable Not applicable Yes (Note 1) ACC006PD-1 combination

Phase II clinical project

ACC006 Chemotherapy for lung squamous cell carcinoma

Combined phase II clinical project

Integrase inhibitor drugs

(Note 2)

Drug research and development and clinical practice 15,446.99 15,446.99 9,156.11 9,156.11 59.27 December 2027 Not applicable Not applicable No

New indications for ulinastatin

research project

Research project (Note 4)

Large R&D technology center

HIV high-end generic drugs

Building purchase project 3,700.00 3,700.00 1,830.21 1,830.21 49.47 December 2026 Not applicable Not applicable No R&D project (Note 3)

Total 38,696.99 29,196.99 19,857.04 19,857.04 68.01 - - - -

1. On August 26, 2021, after deliberation at the 18th meeting of the company’s first board of directors and the 14th meeting of the first board of supervisors, the “Proposal on Changing Investment Projects with Partially Raised Funds” was adopted. The company’s independent directors, board of supervisors and sponsors expressed their agreement on the above matters. The raised funds involved in the change of use include RMB 15.0875 million of unused raised funds of the original project "ACC007 III/IV Phase Clinical Research Project", RMB 33.400 million of unused raised funds of the original project "ACC006BCC Phase II Clinical Research Project", RMB 33.40 million of raised funds of the original project "ACC006BCC Phase II Clinical Research Project", The unused raised funds of the "CC006PD-1 Combination Phase II Clinical Research Project" were RMB 52.60 million and the unused raised funds of the original project "ACC010 I/II Phase II Clinical Research Project" were RMB 53.40 million. The total amount of raised funds was changed to RMB 154.4875 million. Among them, RMB 59.4875 million was used for the new project "Ibond® (Elanovirin Tablets) Phase III clinical and post-marketing research project", and RMB 95.000 million was used for the new project "Research Project for New Indications of Ulinastatin". On September 14, 2021, after deliberation at the company's third extraordinary shareholders' meeting in 2021, the "Proposal on Changing Investment Projects with Partial Raised Funds" was adopted, and the proposal came into effect.

2. On December 24, 2021, after deliberation at the 20th meeting of the company's first board of directors and the 16th meeting of the first board of supervisors, the "Proposal on Changing Part of the Investment Projects with Raised Funds and Adding Reasons for Implementation Changes, Decision-making Procedures and Information Subjects" was adopted. The company's independent directors, board of supervisors and sponsors expressed their agreement on the above matters. The raised funds involved in the change this time are the original project - "ACC006 Lung Squamous Carcinoma Chemotherapy Combination Disclosure Statement (Phase II clinical project for specific fundraising projects)". The total raised funds are 70.10 million yuan (the invested raised funds of 14.8484 million yuan will be replaced by the company's own funds), and it is planned to be all used for the new project - "integrase inhibitor drug product research and development and clinical research projects." On January 11, 2022, after deliberation at the company's first extraordinary general meeting of shareholders in 2022, the "Proposal on Changing Partially Raised Funds Investment Projects and Adding New Implementation Entities" was adopted, and the proposal came into effect.

3. On April 14, 2023, after deliberation at the 12th meeting of the company’s second board of directors and the 11th meeting of the second board of supervisors, the “Proposal on Changing the Investment Projects of Partially Raised Funds” was adopted. The company’s independent directors, board of supervisors and sponsors expressed their agreement on the above matters. The raised funds involved in the change of use this time are all 37 million yuan raised from the original project "R&D Technology Center Building Purchase Project", which is planned to be used entirely for the new project "HIV High-end Generic Drug Research and Development Project". On May 12, 2023, after deliberation at the company's 2022 annual shareholders' meeting, the "Proposal on Changing the Investment Projects of Part of the Raised Funds" was approved, and the proposal came into effect.

4. On June 27, 2025, after deliberation at the fourth meeting of the company's third board of directors and the fourth meeting of the third board of supervisors, the "Proposal on Changing Investment Projects and Amount Adjustments of Partially Raised Funds" was adopted. The company's board of directors, board of supervisors and sponsors expressed their agreement on the above matters. The above matters have been reviewed and approved at the second extraordinary shareholders' meeting on July 14, 2025 and became effective. For details, please refer to the "Announcement of Aidi Pharmaceutical on Changes in Investment Projects and Amount Adjustments of Part of the Raised Funds" disclosed by the company on June 28, 2025 (Announcement No.: 2025-031). The raised funds involved in the change this time are 84.3699 million yuan raised from the original project "Ulinastatin New Indications Research Project", all of which were changed to the existing fundraising project "Integrate Inhibitor Drug Research and Development and Clinical Research Project", and the total investment amount of raised funds was increased accordingly. (Note)

See notes for details of the reason for the change.

Failure to meet the planned progress and the original

None as of December 31, 2025.

Reason (divided into specific fundraising projects)

The feasibility of the project after the change has changed significantly

Not applicable (note).

Description of big changes

Note 1: Due to the current serious homogeneity in the field of anti-tumor innovative drug research and development, relatively scarce medical resources, and significantly increased competitive costs, the company has adjusted its strategic development planning layout and focused its research and development on the anti-HIV, anti-inflammatory and stroke fields, and slowed down the research progress of projects in the anti-tumor field to lock in advantageous tracks and give full play to the company's core competitive advantages.

ACC007 (Ibobond®/Enoverine Tablets) of the original project "ACC007 III/IV Phase Clinical Project" has obtained the "Drug Registration Certificate" for Enovirine Tablets approved and issued by the State Food and Drug Administration on June 25, 2021. According to the requirements, Ibobond needs to complete the Phase III clinical trial. On the basis of this, we will continue to carry out post-marketing research to provide important basis for further rational clinical use of drugs, including real-world research, drug interaction research and carcinogenicity research. Therefore, it is planned to change the original project to the "Ibond® (Anovirine Tablets) Phase III clinical and post-marketing research project" based on the actual progress of the project. According to calculations, the remaining amount of funds raised from the original project "ACC007 Phase III/IV Clinical Project" cannot meet the funding requirements for post-marketing research on ACC007. It is planned to adjust part of the funds from the original project "ACC010 Phase I/II Clinical Project" to meet the funding needs for the new project. In order to improve the efficiency of the use of raised funds and quickly advance the research and development progress of advantageous projects, the company plans to change all the funds from the original projects "ACC006BCC Phase II Clinical Project", "ACC006PD-1 Combination Phase II Clinical Project" and part of the "ACC010I/II Phase Clinical Project" to the new project "Ulinastatin New Indications Research Project". The "Ulinastatin New Indications Research Project" is based on human protein business products, extending the research and development of relevant improved new drugs to the downstream of the industrial chain, and increasing the scope of product indications. If this project is successfully implemented, the company's products will be transformed from crude human protein products into ulinastatin human protein injection drugs, which will be conducive to the company's transformation and upgrading, product structure optimization, and will also help enhance the company's R&D strength, increase product added value, and maintain the company's leading position in the field of human protein R&D and production.

Note 2: Due to the current shortage of medical resources in the field of anti-tumor innovative drug research and development and the significant increase in competitive costs, the company has adjusted its strategic development planning layout and focused its research and development on the anti-HIV, anti-inflammatory and stroke fields, and has slowed down the research progress of projects in the anti-tumor field. In order to better improve the efficiency of the use of raised funds, lock in advantageous tracks, quickly advance the research and development progress of projects in advantageous areas, and give full play to the company's core competitive advantages, the company plans to change all the funds raised from the original project "ACC006 Lung Squamous Carcinoma Combination Chemotherapy Phase II Clinical Project" to the new project "Integrase Inhibitor Drug Research and Development and Clinical Research Project." At present, in cooperation with Changzhou University, the company has completed the design and development of target compounds for new projects, sample preparation and preliminary in vitro activity testing. In the follow-up preclinical pharmacy and pharmacodynamics research, the company will also cooperate with powerful R&D companies to accelerate the process of new drug development. This project will be another core product independently developed by the company in the field of anti-HIV virus after the successful development and launch of the first domestic innovative anti-HIV oral Class 1 drug. The implementation of the new project is in line with national policy requirements and will help improve the effectiveness and safety of anti-HIV drugs and the accessibility of advanced drugs, and provide new treatment options for HIV patients. It will help the company realize drug innovation and industrialize R&D results, enrich product categories, and enhance the company's core competitiveness. The vast market space, encouragement and support from national policies, solid R&D foundation and excellent technical team can ensure the smooth implementation of the project.

Note 3: Because Arcelite failed to reach a final agreement with the property owner on the upfront tax payment target and the transaction price of the building linked to it, the purchase of the target building is on hold; at the same time, as the company's other factory infrastructure is improved, Arcelite's original R&D site layout needs can be met. The company plans to change all the funds raised from the original project "R&D Technology Center Building Purchase Project" to the new project "HIV High-end Generic Drug Research and Development Project." The implementation of the new project is in line with national policy requirements and will help further enrich the company's product categories, optimize the product structure, meet the clinical needs of patients with different treatment cycles, and fill the shortage problem in the domestic AIDS generic drug field; it will help the company realize drug innovation and industrialization of R&D results, lock in advantageous tracks, enhance profitability, enhance the company's core competitiveness, and achieve sustainable development; compared with original drugs, the research and development costs of generic drugs are low, which can not only meet patients' needs for efficacy, but also help reduce their economic pressure. The vast market space, encouragement and support from national policies, solid R&D foundation and excellent technical team can ensure the smooth implementation of the project.

Note 4: The ulinastatin new indication research project (hereinafter referred to as the "original project") has completed a phase I clinical trial at the end of 2021 to evaluate the single-center, randomized, double-blind, placebo-controlled, single and multiple dose escalation safety and tolerability of ulinastatin for injection in healthy Chinese adults. The phase I clinical trial showed that ulinastatin for injection has good safety and tolerability. Since 2022, based on the Phase I clinical trial, the company has actively carried out follow-up clinical trial protocol design verification, external expert demonstration and communication with the Center for Drug Evaluation (CDE) of the State Drug Administration to discuss the proposed indications and their corresponding dosage, timing, efficacy evaluation indicators, etc. Since ulinastatin is extracted from human urine and has a complex material basis, the country's evaluation standards for such injection products are becoming increasingly strict. Although the company has supplemented and improved the systematic scientific research, product quality control strategies, and non-clinical safety research related to ulinastatin's material basis and made relevant progress, CDE still recommends further evaluation and demonstration on the basis of the research and demonstration that has been carried out. Furthermore, on July 27, 2023, the Center for Drug Evaluation of the State Food and Drug Administration issued the "Technical Guiding Principles for Patient-Centered Drug Clinical Trial Design (Trial)", "Technical Guiding Principles for the Implementation of Patient-Centered Drug Clinical Trials (Trial)" and "Technical Guiding Principles for Patient-Centered Drug Benefit-Risk Assessment (Trial)", which put forward higher requirements for drug clinical trials.

Although the original project has been postponed, as of June 2025, CDE still recommends further evaluating and demonstrating the product quality control strategy on the basis of the research and demonstration that has been carried out, and the objective environment of the Drug Evaluation Center of the State Food and Drug Administration has not changed in putting forward higher requirements for drug clinical trials. Therefore, the progress of this project is later than expected, and in the subsequent advancement process, there is still the risk of significant changes in the feasibility of the project. In order to improve the efficiency of the use of raised funds and quickly advance the research and development progress of advantageous projects, after the company studied and conducted feasibility analysis, the remaining raised funds from the original project were invested in the existing raised investment project "integrase inhibitor drug research and development and clinical research project". The original project will continue to be carried out with its own funds or self-raised funds.

The company's existing investment project "Integrase Inhibitor Drug Research and Development and Clinical Research Project" is an integrase inhibitor with a new chemical structure independently developed by the company. In order to fully promote the research and development progress of the project, it is expected that increased R&D investment will be needed to promote the smooth development of subsequent clinical trials of the project. According to calculations, the remaining amount of funds raised for the "integrase inhibitor drug research and development and clinical research project" cannot meet the funding needs for pre-NDA research on integrase inhibitor drugs. It is planned to change the remaining funds raised from the original project to the "integrase inhibitor drug research and development and clinical research project" to meet the funding needs for the development of the integrase inhibitor project.

Schedule 3:

Comparison table of benefits achieved by investment projects with previously raised funds

As of December 31, 2025

Prepared by: Jiangsu Aidi Pharmaceutical Group Co., Ltd. Unit: RMB 10,000

Actual investment projects Actual benefits (net profit)

Accumulation of investment projects on the deadline. Accumulation of investment projects on the deadline. Whether the expected promised benefits have been achieved.

Calculated capacity utilization rate to achieve benefits Benefit number Project name 2022 2023 2024 2025

1 ACC008 III/IV phase clinical project Not applicable Not committed (Note 1) Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable

Ibond® (Enovirine Tablets) Phase III clinical and post-marketing

2 Not applicable Not committed (Note 2) Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable to research projects

3 Integrate inhibitor drug development and clinical research projects Not applicable Not committed Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable

4 HIV high-end generic drug R&D project Not applicable Not committed Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable

5 API production, R&D and supporting facilities projects 75% Note 3 Not applicable Not applicable Not applicable 177.91 177.91 Not applicable

Note 1: The ACC008 Phase III/IV clinical project is mainly a phase III clinical study before the launch of the company's new anti-HIV drug ACC008 (Enomide Tablets) and a continued phase IV study after the launch. It examines the efficacy and adverse reactions of the drug under widespread use, evaluates the relationship between benefits and risks when used in general or special populations, and improves dosage, etc. Through real-world research, it can not only verify the results of pre-market clinical trials and correct their deviations, but also make up for the lack of data and information in pre-market clinical trials, providing an important basis for further rational clinical use of drugs. This project is not included in the company's prospectus The book promises benefits. After the new drug of this product is approved for marketing, the sales revenue of this type of drug in 2023, 2024 and 2025 will be 48.8438 million yuan, 133.5427 million yuan and 254.0549 million yuan respectively.

Note 2: The Phase III clinical and post-marketing research projects of Ibond® (Enovirine Tablets) are mainly the pre-marketing Phase III clinical research of the company’s new anti-HIV drug ACC007 (Inovirine Tablets) and the ongoing post-marketing Phase IV research. Through the phased post-marketing research work of Ibobond®, the efficacy and adverse reactions of the drug under widespread use conditions will be investigated, and the evaluation will be carried out in ordinary Or the relationship between benefits and risks of use in special groups, improving dosage, etc., so as to verify the results of pre-market clinical trials and correct their deviations, make up for the lack of data and information in pre-market clinical trials, and provide an important basis for further rational clinical use of drugs. This project did not promise benefits in the company's prospectus. After the new drug of this product is approved for marketing, in 2022, 2023, The sales revenue of this type of drugs in 2024 and 2025 will be 33.495 million yuan, 24.735 million yuan, 16.3569 million yuan and 30.3295 million yuan respectively.

Note 3: The company has built a new API production and R&D base in Yangzhou Biotechnology Park through its subsidiary Aidi Pharmaceutical, creating a domestic first-class high-end chemical API production and R&D platform with software and hardware facilities, laying a good foundation for the company's further development. This project is the first phase of the overall planning of the base. After the project is put into operation, it will mainly produce ACC007 API, providing key raw material guarantee for the future production of Aidi Pharmaceutical's ACC007, ACC008 and other preparation products. The estimated construction period is 2 years, the project's financial internal rate of return is 27.73% (after income tax), and the investment payback period is 6.50 years (after income tax, including the construction period), which has good economic benefits. The API production R&D and supporting facilities project has obtained a production license, and this project will be approved for production in June 2024. The actual benefit of this project in 2025 is a net profit of 1.7791 million yuan, reaching the expected benefit in the corresponding year.

Note 4: Except for the API production, research and development and supporting facilities projects, the company has not made any commitment to the benefits of the use of other previously raised funds, and the benefits of other previously raised funds investment projects cannot be calculated separately.